Matias Trillini

发表

The Global Burden of Cancer 2013.

Nobhojit Roy, Ivy Shiue, Reza Malekzadeh, 2015, JAMA oncology.

Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy.

G. Remuzzi, P. Ruggenenti, N. Rubis, 2023, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

Bernadette A. Thomas, Alan D. Lopez, Mark D. Huffman, 2015, The Lancet.

Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial

G. Remuzzi, F. Gaspari, D. Warnock, 2018, Journal of the Endocrine Society.

Managing end-stage renal disease in the elderly: state-of-the-art, challenges and opportunities

M. Trillini, M. Kasa, G. Gentile, 2013 .

Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.

G. Nijpels, F. Rutters, H. Mischak, 2020, The lancet. Diabetes & endocrinology.

Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.

G. Remuzzi, C. Zoccali, M. Trillini, 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Infective endocarditis mimics ANCA associated glomerulonephritis.

M. Trillini, Mohammad Reza Ardalan, Matias Trillini, 2012, Caspian journal of internal medicine.

Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.

D. Maahs, H. Mischak, G. Navis, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Chronic kidney disease and risk of mortality, cardiovascular events or end-stage renal disease in older patients with hypertension

M. Trillini, G. Gentile, Matias Trillini, 2012, Expert review of cardiovascular therapy.

Epidemiology of End-Stage Renal Failure: The Burden of Kidney Diseases to Global Health

N. Perico, G. Remuzzi, M. Trillini, 2017 .

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

Gunn Marit Aasvang, Daniel C. Casey, D. Mozaffarian, 2015, The Lancet.

Preventing microalbuminuria with benazepril, valsartan, and benazepril–valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study

G. Remuzzi, F. Gaspari, M. Trillini, 2021, PLoS medicine.

Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

Bernadette A. Thomas, Alan D. Lopez, Mark D. Huffman, 2015, The Lancet.

Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial

G. Remuzzi, M. Trillini, P. Ruggenenti, 2016, Diabetes.

In type-2 diabetics with abdominal obesity, hyperfiltration is a risk factor for accelerated GFR decline and nephropathy. In this academic, single-center, parallel-group, Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) trial (ClinicalTRials.gov number: NCT01213212), consenting >18-year

G. Remuzzi, M. Trillini, P. Ruggenenti, 2016 .

Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.

G. Remuzzi, F. Gaspari, M. Trillini, 2018, The lancet. Diabetes & endocrinology.

Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.

L. Antiga, N. Perico, G. Remuzzi, 2016, Clinical journal of the American Society of Nephrology : CJASN.

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Eddie B. S. Tan, Nishit P. Parikh, Rajan K. Patel, 2023, The Lancet.

Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial

G. Remuzzi, P. Manunta, F. Gaspari, 2019, Diabetes, obesity & metabolism.

Characteristics of high‐ and low‐risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes

G. Nijpels, F. Rutters, H. Mischak, 2018, Diabetic medicine : a journal of the British Diabetic Association.

Long-Term Kidney and Systemic Effects Of Calorie Restriction in Overweight or Obese Type 2 Diabetic Patients (C.Re.S.O. 2 Randomized Controlled Trial).

G. Remuzzi, F. Gaspari, M. Trillini, 2022, Diabetes research and clinical practice.

Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial

N. Perico, G. Remuzzi, A. Remuzzi, 2019, PLoS medicine.

Mutation Analysis of PKD1 and PKD2 Genes in a Large Italian Cohort Reveals Novel Pathogenic Variants Including a Novel Complex Rearrangement

N. Perico, G. Remuzzi, A. Benigni, 2023, Nephron.

Iohexol Plasma Clearance Measurement Protocol Standardization for Adults - a Consensus Paper of the European Kidney Function Consortium.

Fabiola Carrara, H. Pottel, R. Palsson, 2024, Kidney international.

Diffusion magnetic resonance imaging for kidney cyst volume quantification and non-cystic tissue characterisation in ADPKD

N. Perico, G. Remuzzi, A. Remuzzi, 2023, European Radiology.

Effects of Octreotide–Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial

N. Perico, G. Remuzzi, A. Remuzzi, 2023, Clinical journal of the American Society of Nephrology : CJASN.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.